Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement

Fig. 3

Forest plots of XRCC1 Arg399Gln polymorphisms and clinical outcomes in platinum-based chemotherapy. a Dominant model of association between 399Gln and objective response relative to 399Arg; An OR >1 (or <1) indicates that the 399Gln is more (or less) likely to show response than 399Arg. b Homozygous model of association between 399Gln and overall survival relative to 399Arg; An HR > 1 (or <1) indicates that the 399Gln is more (or less) likely to show worse overall survival than 399Arg. c Homozygous model of association between 399Gln and progression free survival relative to 399Arg. An HR > 1 (or <1) indicates that the 399Gln is more (or less) likely to show worse progression free survival than 399Arg

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us